Post Marketing Surveillance of Telostop TAB (Telmisartan/Rosuvastatin) for Evaluating the Safety and Efficacy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Post-marketing surveillance of Telostop TAB (Telmisartan/Rosuvastatin)
Condition or disease
Telostop TAB is fixed-dose combination of telmisartan and rosuvastatin, which was approved in 2015 in the Republic of Korea for the treatment of patients with hypertention and dyslipidemia. A post-marketing surveillance was conducted following the approval to obtain data on the safety and efficacy of Telostop TAB in real-world practice.
Incidence of adverse event after this drug administration in general medical practice [ Time Frame: 24 weeks ]
Any adverse events occurred after this drug dosing will be recorded. Description of adverse event(s) including type of adverse event(s), onset/end date, severity, action taken, causal relationship to the drug and investigator's view on the adverse event(s) will be captured, whether it is related to the drug or not and until follow up visit more than 1 time during the surveillance period.
Lab abnormalities and changes in vital signs are considered to be adverse events only if they result in discontinuation from the study, necessitate therapeutic medical intervention, and/or if the investigator considers them to be adverse events.
Secondary Outcome Measures :
The change from baseline to week 24 in the LDL cholesterol [ Time Frame: 24 weeks ]
LDL cholesterol is measured before administration of the drug and within 24 weeks after administration.
The change from baseline to week 24 in the blood pressure [ Time Frame: 24 weeks ]
Blood pressure is measured before administration of the drug and within 24 weeks after administration.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
19 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
residents of Korea, in real-world practice
The patient who is first prescribed and administered Telostop plus Tab.
The patients who are overreacting to this drug or its components
The patients to the "Do not administer to the next patient" section of the approved instructions for use